{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T10:46:17Z","timestamp":1782384377870,"version":"3.54.5"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100000272","name":"NIHR","doi-asserted-by":"crossref","award":["NIHR303122"],"award-info":[{"award-number":["NIHR303122"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40263-026-01299-4","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T17:35:20Z","timestamp":1779384920000},"page":"901-920","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Evolving Pharmacological Landscape for Paediatric and Adult ADHD"],"prefix":"10.1007","volume":"40","author":[{"given":"Guilherme","family":"Fusetto Veronesi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Pirolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5877-8075","authenticated-orcid":false,"given":"Samuele","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"1299_CR1","doi-asserted-by":"publisher","first-page":"4823","DOI":"10.1038\/s41380-023-02228-3","volume":"28","author":"S Cortese","year":"2023","unstructured":"Cortese S, Song M, Farhat LC, Yon DK, Lee SW, Kim MS, et al. Incidence, prevalence, and global burden of ADHD from 1990 to 2019 across 204 countries: data, with critical re-analysis, from the Global Burden of Disease study. Mol Psychiatry. 2023;28:4823\u201330. https:\/\/doi.org\/10.1038\/s41380-023-02228-3.","journal-title":"Mol Psychiatry"},{"key":"1299_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1037\/a0027347","volume":"121","author":"EG Willcutt","year":"2012","unstructured":"Willcutt EG, Nigg JT, Pennington BF, Solanto MV, Rohde LA, Tannock R, et al. Validity of DSM-IV attention deficit\/hyperactivity disorder symptom dimensions and subtypes. J Abnorm Psychol. 2012;121:991\u20131010. https:\/\/doi.org\/10.1037\/a0027347.","journal-title":"J Abnorm Psychol"},{"key":"1299_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1192\/bjp.bp.107.048827","volume":"194","author":"V Simon","year":"2009","unstructured":"Simon V, Czobor P, B\u00e1lint S, M\u00e9sz\u00e1ros \u00c1, Bitter I. Prevalence and correlates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J Psychiatry. 2009;194:204\u201311. https:\/\/doi.org\/10.1192\/bjp.bp.107.048827.","journal-title":"Br J Psychiatry"},{"key":"1299_CR4","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.17m11607","author":"M-H Chen","year":"2018","unstructured":"Chen M-H, Pan T-L, Hsu J-W, Huang K-L, Su T-P, Li C-T, et al. Risk of type 2 diabetes in adolescents and young adults with attention-deficit\/hyperactivity disorder: a nationwide longitudinal study. J Clin Psychiatry. 2018. https:\/\/doi.org\/10.4088\/JCP.17m11607.","journal-title":"J Clin Psychiatry"},{"key":"1299_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0204516","volume":"13","author":"Q Chen","year":"2018","unstructured":"Chen Q, Hartman CA, Haavik J, Harro J, Klungs\u00f8yr K, Hegvik T-A, et al. Common psychiatric and metabolic comorbidity of adult attention-deficit\/hyperactivity disorder: a population-based cross-sectional study. PLoS ONE. 2018;13:e0204516. https:\/\/doi.org\/10.1371\/journal.pone.0204516.","journal-title":"PLoS ONE"},{"key":"1299_CR6","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1176\/appi.ajp.2015.15020266","volume":"173","author":"S Cortese","year":"2016","unstructured":"Cortese S, Moreira-Maia CR, St. Fleur D, Morcillo-Pe\u00f1alver C, Rohde LA, Faraone SV. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry. 2016;173:34\u201343. https:\/\/doi.org\/10.1176\/appi.ajp.2015.15020266.","journal-title":"Am J Psychiatry"},{"key":"1299_CR7","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1192\/bjpo.bp.116.004317","volume":"3","author":"S Osland","year":"2017","unstructured":"Osland S, Hirsch L, Pringsheim T. Smoking, alcohol and drug use in youth and adults with attention-deficit hyperactivity disorder. BJPsych Open. 2017;3:141\u20136. https:\/\/doi.org\/10.1192\/bjpo.bp.116.004317.","journal-title":"BJPsych Open"},{"key":"1299_CR8","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/15374416.2016.1266644","volume":"47","author":"R Ros","year":"2018","unstructured":"Ros R, Graziano PA. Social functioning in children with or at risk for attention deficit\/hyperactivity disorder: a meta-analytic review. J Clin Child Adolesc Psychol. 2018;47:213\u201335. https:\/\/doi.org\/10.1080\/15374416.2016.1266644.","journal-title":"J Clin Child Adolesc Psychol"},{"key":"1299_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamapaediatrics.2017.0691","volume":"171","author":"M Fleming","year":"2017","unstructured":"Fleming M, Fitton CA, Steiner MFC, McLay JS, Clark D, King A, et al. Educational and health outcomes of children treated for attention-deficit\/hyperactivity disorder. JAMA Pediatr. 2017;171:e170691. https:\/\/doi.org\/10.1001\/jamapaediatrics.2017.0691.","journal-title":"JAMA Pediatr"},{"key":"1299_CR10","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1056\/NEJMra1917069","volume":"383","author":"S Cortese","year":"2020","unstructured":"Cortese S. Pharmacologic treatment of attention deficit\u2013hyperactivity disorder. N Engl J Med. 2020;383:1050\u20136. https:\/\/doi.org\/10.1056\/NEJMra1917069.","journal-title":"N Engl J Med"},{"key":"1299_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2165\/00003088-200544060-00002","volume":"44","author":"J-M Sauer","year":"2005","unstructured":"Sauer J-M, Ring BJ, Witcher JW. Clinical pharmacokinetics of atomoxetine: Clin Pharmacokinet. 2005;44:571\u201390. https:\/\/doi.org\/10.2165\/00003088-200544060-00002.","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 8","key":"1299_CR12","first-page":"32","volume":"67","author":"TE Wilens","year":"2006","unstructured":"Wilens TE. Mechanism of action of agents used in attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2006;67(Suppl 8):32\u20138.","journal-title":"J Clin Psychiatry"},{"key":"1299_CR13","doi-asserted-by":"publisher","first-page":"285","DOI":"10.2147\/JEP.S256586","volume":"12","author":"C Yu","year":"2020","unstructured":"Yu C, Garcia-Olivares J, Candler S, Schwabe S, Maletic V. New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties. J Exp Pharmacol. 2020;12:285\u2013300. https:\/\/doi.org\/10.2147\/JEP.S256586.","journal-title":"J Exp Pharmacol"},{"key":"1299_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085875","volume":"391","author":"CJ Gosling","year":"2025","unstructured":"Gosling CJ, Garcia-Argibay M, De Prisco M, Arrondo G, Ayrolles A, Antoun S, et al. Benefits and harms of ADHD interventions: umbrella review and platform for shared decision making. BMJ. 2025;391:e085875. https:\/\/doi.org\/10.1136\/bmj-2025-085875.","journal-title":"BMJ"},{"key":"1299_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2024-083658","volume":"390","author":"L Zhang","year":"2025","unstructured":"Zhang L, Zhu N, Sj\u00f6lander A, Nourredine M, Li L, Garcia-Argibay M, et al. ADHD drug treatment and risk of suicidal behaviours, substance misuse, accidental injuries, transport accidents, and criminality: emulation of target trials. BMJ. 2025;390:e083658. https:\/\/doi.org\/10.1136\/bmj-2024-083658.","journal-title":"BMJ"},{"key":"1299_CR16","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jama.2024.0851","volume":"331","author":"L Li","year":"2024","unstructured":"Li L, Zhu N, Zhang L, Kuja-Halkola R, D\u2019Onofrio BM, Brikell I, et al. ADHD pharmacotherapy and mortality in individuals with ADHD. JAMA. 2024;331:850. https:\/\/doi.org\/10.1001\/jama.2024.0851.","journal-title":"JAMA"},{"key":"1299_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1176\/appi.ajp.2019.18111296","volume":"176","author":"A-FM Matthijssen","year":"2019","unstructured":"Matthijssen A-FM, Dietrich A, Bierens M, Kleine Deters R, Van De Loo-Neus GHH, Van Den Hoofdakker BJ, et al. Continued benefits of methylphenidate in ADHD after 2 years in clinical practice: a randomised placebo-controlled discontinuation study. Am J Psychiatry. 2019;176:754\u201362. https:\/\/doi.org\/10.1176\/appi.ajp.2019.18111296.","journal-title":"Am J Psychiatry"},{"key":"1299_CR18","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2023.4294","volume":"81","author":"L Zhang","year":"2024","unstructured":"Zhang L, Li L, Andell P, Garcia-Argibay M, Quinn PD, D\u2019Onofrio BM, et al. Attention-deficit\/hyperactivity disorder medications and long-term risk of cardiovascular diseases. JAMA Psychiat. 2024;81:178. https:\/\/doi.org\/10.1001\/jamapsychiatry.2023.4294.","journal-title":"JAMA Psychiat"},{"key":"1299_CR19","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S2215-0366(23)00042-1","volume":"10","author":"KKC Man","year":"2023","unstructured":"Man KKC, H\u00e4ge A, Banaschewski T, Inglis SK, Buitelaar J, Carucci S, et al. Long-term safety of methylphenidate in children and adolescents with ADHD: 2-year outcomes of the Attention Deficit Hyperactivity Disorder Drugs Use Chronic Effects (ADDUCE) study. Lancet Psychiatry. 2023;10:323\u201333. https:\/\/doi.org\/10.1016\/S2215-0366(23)00042-1.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR20","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.neubiorev.2020.09.031","volume":"120","author":"S Carucci","year":"2021","unstructured":"Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. Long term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;120:509\u201325. https:\/\/doi.org\/10.1016\/j.neubiorev.2020.09.031.","journal-title":"Neurosci Biobehav Rev"},{"key":"1299_CR21","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2019-2528","volume":"144","author":"ML Wolraich","year":"2019","unstructured":"Wolraich ML, Hagan JF, Allan C, Chan E, Davison D, Earls M, et al. Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit\/hyperactivity disorder in children and adolescents. Pediatrics. 2019;144:e20192528. https:\/\/doi.org\/10.1542\/peds.2019-2528.","journal-title":"Pediatrics"},{"key":"1299_CR22","unstructured":"National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management [NICE Guideline No. 87]. NICE; 2018 [cited 2025 Dec 26]. https:\/\/www.nice.org.uk\/guidance\/ng87. Accessed 26 Dec 2025."},{"key":"1299_CR23","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.eurpsy.2018.11.001","volume":"56","author":"JJS Kooij","year":"2019","unstructured":"Kooij JJS, Bijlenga D, Salerno L, Jaeschke R, Bitter I, Bal\u00e1zs J, et al. Updated European consensus statement on diagnosis and treatment of adult ADHD. Eur Psychiatry. 2019;56:14\u201334. https:\/\/doi.org\/10.1016\/j.eurpsy.2018.11.001.","journal-title":"Eur Psychiatry"},{"key":"1299_CR24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","volume":"5","author":"S Cortese","year":"2018","unstructured":"Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5:727\u201338. https:\/\/doi.org\/10.1016\/S2215-0366(18)30269-4.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1002\/wps.20765","volume":"19","author":"M Solmi","year":"2020","unstructured":"Solmi M, Fornaro M, Ostinelli EG, Zangani C, Croatto G, Monaco F, et al. Safety of 80 antidepressants, antipsychotics, anti\u2010attention\u2010deficit\/hyperactivity medications and mood stabilisers in children and adolescents with psychiatric disorders: a large scale systematic meta\u2010review of 78 adverse effects. World Psychiatry. 2020;19:214\u201332. https:\/\/doi.org\/10.1002\/wps.20765.","journal-title":"World Psychiatry"},{"key":"1299_CR26","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2215-0366(25)00062-8","volume":"12","author":"LC Farhat","year":"2025","unstructured":"Farhat LC, Lannes A, Del Giovane C, Parlatini V, Garcia-Argibay M, Ostinelli EG, et al. Comparative cardiovascular safety of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2025;12:355\u201365. https:\/\/doi.org\/10.1016\/S2215-0366(25)00062-8.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR27","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jcpp.12036","volume":"54","author":"S Cortese","year":"2013","unstructured":"Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, et al. Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry. 2013;54:227\u201346. https:\/\/doi.org\/10.1111\/jcpp.12036.","journal-title":"J Child Psychol Psychiatry"},{"key":"1299_CR28","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1111\/j.1527-3458.2007.00026.x","volume":"13","author":"DJ Posey","year":"2007","unstructured":"Posey DJ, McDougle CJ. Guanfacine and guanfacine extended release: treatment for ADHD and related disorders. CNS Drug Rev. 2007;13:465\u201374. https:\/\/doi.org\/10.1111\/j.1527-3458.2007.00026.x.","journal-title":"CNS Drug Rev"},{"key":"1299_CR29","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40263-016-0349-0","volume":"30","author":"VA Reed","year":"2016","unstructured":"Reed VA, Buitelaar JK, Anand E, Day KA, Treuer T, Upadhyaya HP, et al. The safety of atomoxetine for the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a comprehensive review of over a decade of research. CNS Drugs. 2016;30:603\u201328. https:\/\/doi.org\/10.1007\/s40263-016-0349-0.","journal-title":"CNS Drugs"},{"key":"1299_CR30","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1192\/bjp.bp.111.096594","volume":"200","author":"S Leucht","year":"2012","unstructured":"Leucht S, Hierl S, Kissling W, Dold M, Davis JM. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry. 2012;200:97\u2013106. https:\/\/doi.org\/10.1192\/bjp.bp.111.096594.","journal-title":"Br J Psychiatry"},{"key":"1299_CR31","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1586\/ern.13.31","volume":"13","author":"P Hodgkins","year":"2013","unstructured":"Hodgkins P, Dittmann RW, Sorooshian S, Banaschewski T. Individual treatment response in attention-deficit\/hyperactivity disorder: broadening perspectives and improving assessments. Expert Rev Neurother. 2013;13:425\u201333. https:\/\/doi.org\/10.1586\/ern.13.31.","journal-title":"Expert Rev Neurother"},{"key":"1299_CR32","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1089\/cap.2012.0085","volume":"23","author":"BE Ramtvedt","year":"2013","unstructured":"Ramtvedt BE, R\u00f8in\u00e5s E, Aabech HS, Sundet KS. Clinical gains from including both dextroamphetamine and methylphenidate in stimulant trials. J Child Adolesc Psychopharmacol. 2013;23:597\u2013604. https:\/\/doi.org\/10.1089\/cap.2012.0085.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1299_CR33","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/108705470000300403","volume":"3","author":"LE Arnold","year":"2000","unstructured":"Arnold LE. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3:200\u201311. https:\/\/doi.org\/10.1177\/108705470000300403.","journal-title":"J Atten Disord"},{"key":"1299_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S2215-0366(24)00396-1","volume":"12","author":"M Garcia-Argibay","year":"2025","unstructured":"Garcia-Argibay M, Chang Z, Brikell I, Kuja-Halkola R, D\u2019Onofrio BM, Lichtenstein P, et al. Evaluating ADHD medication trial representativeness: a Swedish population-based study comparing hypothetically trial-eligible and trial-ineligible individuals. Lancet Psychiatry. 2025;12:131\u20139. https:\/\/doi.org\/10.1016\/S2215-0366(24)00396-1.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR35","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1176\/appi.ajp.2007.05091676","volume":"165","author":"JH Newcorn","year":"2008","unstructured":"Newcorn JH, Kratochvil CJ, Allen AJ, Casat CD, Ruff DD, Moore RJ, et al. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry. 2008;165:721\u201330. https:\/\/doi.org\/10.1176\/appi.ajp.2007.05091676.","journal-title":"Am J Psychiatry"},{"key":"1299_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2025.102571","volume":"118","author":"U Njardvik","year":"2025","unstructured":"Njardvik U, Wergeland GJ, Riise EN, Hannesdottir DKr, \u00d6st L-G. Psychiatric comorbidity in children and adolescents with ADHD: a systematic review and meta-analysis. Clin Psychol Rev. 2025;118:102571. https:\/\/doi.org\/10.1016\/j.cpr.2025.102571.","journal-title":"Clin Psychol Rev"},{"key":"1299_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105209","volume":"151","author":"CA Hartman","year":"2023","unstructured":"Hartman CA, Larsson H, Vos M, Bellato A, Libutzki B, Solberg BS, et al. Anxiety, mood, and substance use disorders in adult men and women with and without attention-deficit\/hyperactivity disorder: a substantive and methodological overview. Neurosci Biobehav Rev. 2023;151:105209. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105209.","journal-title":"Neurosci Biobehav Rev"},{"key":"1299_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2024.104135","volume":"99","author":"J Kang","year":"2024","unstructured":"Kang J, Lee H, Kim S, Kim HJ, Lee H, Kwon R, et al. Comorbid health conditions in people with attention-deficit\/hyperactivity disorders: an umbrella review of systematic reviews and meta-analyses. Asian J Psychiatry. 2024;99:104135. https:\/\/doi.org\/10.1016\/j.ajp.2024.104135.","journal-title":"Asian J Psychiatry"},{"key":"1299_CR39","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1038\/s41380-019-0540-z","volume":"26","author":"T-A Hegvik","year":"2021","unstructured":"Hegvik T-A, Wal\u00f8en K, Pandey SK, Faraone SV, Haavik J, Zayats T. Druggable genome in attention deficit\/hyperactivity disorder and its co-morbid conditions. New avenues for treatment. Mol Psychiatry. 2021;26:4004\u201315. https:\/\/doi.org\/10.1038\/s41380-019-0540-z.","journal-title":"Mol Psychiatry"},{"key":"1299_CR40","doi-asserted-by":"publisher","first-page":"37018","DOI":"10.52965\/001c.37018","volume":"10","author":"HW Haddad","year":"2022","unstructured":"Haddad HW, Hankey PB, Ko J, Eswani Z, Bhatti P, Edinoff AN, et al. Viloxazine, a non-stimulant norepinephrine reuptake inhibitor, for the treatment of attention deficit hyperactivity disorder: a 3 year update. Health Psychol Res United States. 2022;10:37018. https:\/\/doi.org\/10.52965\/001c.37018.","journal-title":"Health Psychol Res. United States"},{"key":"1299_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2023.105149","volume":"149","author":"S Cortese","year":"2023","unstructured":"Cortese S, McGinn K, H\u00f8jlund M, Apter A, Arango C, Baeza I, et al. The future of child and adolescent clinical psychopharmacology: a systematic review of Phase 2, 3, or 4 randomised controlled trials of pharmacologic agents without regulatory approval or for unapproved indications. Neurosci Biobehav Rev. 2023;149:105149. https:\/\/doi.org\/10.1016\/j.neubiorev.2023.105149.","journal-title":"Neurosci Biobehav Rev"},{"key":"1299_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105774","volume":"163","author":"GF Veronesi","year":"2024","unstructured":"Veronesi GF, Gabellone A, Tomlinson A, Solmi M, Correll CU, Cortese S. Treatments in the pipeline for attention-deficit\/hyperactivity disorder (ADHD) in adults. Neurosci Biobehav Rev. 2024;163:105774. https:\/\/doi.org\/10.1016\/j.neubiorev.2024.105774.","journal-title":"Neurosci Biobehav Rev"},{"key":"1299_CR43","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S2215-0366(24)00370-5","volume":"12","author":"DJ Nutt","year":"2025","unstructured":"Nutt DJ. Drug development in psychiatry: 50 years of failure and how to resuscitate it. Lancet Psychiatry. 2025;12:228\u201338. https:\/\/doi.org\/10.1016\/S2215-0366(24)00370-5.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR44","unstructured":"Department of Health and Human Services. Clinical trials registration and results information submission. Fed. Regist. 2016 [cited 2025 Dec 27]. https:\/\/www.federalregister.gov\/documents\/2016\/09\/21\/2016-22129\/clinical-trials-registration-and-results-information-submission. Accessed 27 Dec 2025."},{"key":"1299_CR45","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","volume":"25","author":"J Zohar","year":"2015","unstructured":"Zohar J, Stahl S, Moller H-J, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015;25:2318\u201325. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.08.019.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1299_CR46","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/hup.1154","volume":"25","author":"M Mohammadi","year":"2010","unstructured":"Mohammadi M, Kazemi M, Zia E, Rezazadeh S, Tabrizi M, Akhondzadeh S. Amantadine versus methylphenidate in children and adolescents with attention deficit\/hyperactivity disorder: a randomised, double\u2010blind trial. Hum Psychopharmacol Clin Exp. 2010;25:560\u20135. https:\/\/doi.org\/10.1002\/hup.1154.","journal-title":"Hum Psychopharmacol Clin Exp"},{"key":"1299_CR47","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1089\/cap.2019.0085","volume":"30","author":"AC Childress","year":"2020","unstructured":"Childress AC, Kollins SH, Foehl HC, Newcorn JH, Mattingly G, Kupper RJ, et al. Randomised, double-blind, placebo-controlled, flexible-dose titration study of methylphenidate hydrochloride extended-release capsules (Aptensio XR) in preschool children with attention-deficit\/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2020;30:58\u201368. https:\/\/doi.org\/10.1089\/cap.2019.0085.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1299_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2025.06.023","author":"CL Ward","year":"2025","unstructured":"Ward CL, Childress AC, Jin N, Turkoglu O, Skubiak T, Wilens TE. Centanafadine for attention-deficit\/hyperactivity disorder in adolescents: a randomised clinical trial. J Am Acad Child Adolesc Psychiatry. 2025. https:\/\/doi.org\/10.1016\/j.jaac.2025.06.023.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1299_CR49","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1089\/cap.2018.0083","volume":"29","author":"RL Findling","year":"2019","unstructured":"Findling RL, Adler LA, Spencer TJ, Goldman R, Hopkins SC, Koblan KS, et al. Dasotraline in children with attention-deficit\/hyperactivity disorder: a six-week, placebo-controlled, fixed-dose trial. J Child Adolesc Psychopharmacol. 2019;29:80\u20139. https:\/\/doi.org\/10.1089\/cap.2018.0083.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"1299_CR50","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1177\/10870547211073477","volume":"26","author":"S Wigal","year":"2022","unstructured":"Wigal S, Tsai J, Bates JA, Sarma K, Tortorich D, Zhu H, et al. A randomised, placebo-controlled laboratory classroom study of the efficacy and safety of dasotraline in children with ADHD. J Atten Disord. 2022;26:1357\u201368. https:\/\/doi.org\/10.1177\/10870547211073477.","journal-title":"J Atten Disord"},{"key":"1299_CR51","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/j.jaac.2022.03.034","volume":"61","author":"AC Childress","year":"2022","unstructured":"Childress AC, Lloyd E, Jacobsen L, Gunawardhana L, Johnson SA, Findling RL. Efficacy and safety of lisdexamfetamine in preschool children with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2022;61:1423\u201334. https:\/\/doi.org\/10.1016\/j.jaac.2022.03.034.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1299_CR52","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2352-4642(22)00279-6","volume":"6","author":"LS Sugaya","year":"2022","unstructured":"Sugaya LS, Salum GA, De Sousa Gurgel W, De Morais EM, Del Prette G, Pilatti CD, et al. Efficacy and safety of methylphenidate and behavioural parent training for children aged 3\u20135 years with attention-deficit hyperactivity disorder: a randomised, double-blind, placebo-controlled, and sham behavioural parent training-controlled trial. Lancet Child Adolesc Health. 2022;6:845\u201356. https:\/\/doi.org\/10.1016\/S2352-4642(22)00279-6.","journal-title":"Lancet Child Adolesc Health"},{"key":"1299_CR53","doi-asserted-by":"publisher","DOI":"10.17116\/jnevro202212211162","volume":"122","author":"NN Zavadenko","year":"2022","unstructured":"Zavadenko NN, Makushkin EV, Gaynetdinova DD, Kolokolov OV, Malinina EV, Antipenko EA, et al. Treatment of attention deficit hyperactivity disorder in children: results of a multicenter, randomised, double-blind, placebo-controlled clinical trial. Zhurnal nevrologii i psikhiatrii im SS Korsakova. 2022;122:62. https:\/\/doi.org\/10.17116\/jnevro202212211162.","journal-title":"Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova"},{"key":"1299_CR54","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1097\/JCP.0000000000001575","volume":"42","author":"LA Adler","year":"2022","unstructured":"Adler LA, Adams J, Madera-McDonough J, Kohegyi E, Hobart M, Chang D, et al. Efficacy, safety, and tolerability of centanafadine sustained-release tablets in adults with attention-deficit\/hyperactivity disorder: results of 2 phase 3, randomised, double-blind, multicenter, placebo-controlled trials. J Clin Psychopharmacol. 2022;42:429\u201339. https:\/\/doi.org\/10.1097\/JCP.0000000000001575.","journal-title":"J Clin Psychopharmacol"},{"key":"1299_CR55","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.2147\/NDT.S242084","volume":"16","author":"SB Wigal","year":"2020","unstructured":"Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, et al. Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: Results of Phase 2 studies. Neuropsychiatr Dis Treat. 2020;16:1411\u201326. https:\/\/doi.org\/10.2147\/NDT.S242084.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"1299_CR56","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/YIC.0000000000000333","volume":"36","author":"LA Adler","year":"2021","unstructured":"Adler LA, Goldman R, Hopkins SC, Koblan KS, Kent J, Hsu J, et al. Dasotraline in adults with attention deficit hyperactivity disorder: a placebo-controlled, fixed-dose trial. Int Clin Psychopharmacol. 2021;36:117\u201325. https:\/\/doi.org\/10.1097\/YIC.0000000000000333.","journal-title":"Int Clin Psychopharmacol"},{"key":"1299_CR57","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s40263-018-0503-y","volume":"32","author":"TL Wigal","year":"2018","unstructured":"Wigal TL, Newcorn JH, Handal N, Wigal SB, Mulligan I, Schmith V, et al. A double-blind, placebo-controlled, Phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit\/hyperactivity disorder (ADHD). CNS Drugs. 2018;32:289\u2013301. https:\/\/doi.org\/10.1007\/s40263-018-0503-y.","journal-title":"CNS Drugs"},{"key":"1299_CR58","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/j.euroneuro.2017.05.005","volume":"27","author":"RE Cooper","year":"2017","unstructured":"Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. Cannabinoids in attention-deficit\/hyperactivity disorder: a randomised-controlled trial. Eur Neuropsychopharmacol. 2017;27:795\u2013808. https:\/\/doi.org\/10.1016\/j.euroneuro.2017.05.005.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1299_CR59","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.23m14934","author":"CBH Surman","year":"2023","unstructured":"Surman CBH, Walsh DM, Horick N, DiSalvo M, Vater CH, Kaufman D. Solriamfetol for attention-deficit\/hyperactivity disorder in adults: a double-blind placebo-controlled pilot study. J Clin Psychiatry. 2023. https:\/\/doi.org\/10.4088\/JCP.23m14934.","journal-title":"J Clin Psychiatry"},{"key":"1299_CR60","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1177\/0269881119832538","volume":"33","author":"J Biederman","year":"2019","unstructured":"Biederman J, Lindsten A, Sluth LB, Petersen ML, Ettrup A, Eriksen H-LF, et al. Vortioxetine for attention deficit hyperactivity disorder in adults: a randomised, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol. 2019;33:511\u201321. https:\/\/doi.org\/10.1177\/0269881119832538.","journal-title":"J Psychopharmacol"},{"key":"1299_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-66670-3","author":"Y Li","year":"2025","unstructured":"Li Y, Meng Y, Li N, Zhao J, Li R, Bai Q, et al. Structural basis for pharmacotherapeutic action of triple reuptake inhibitors. Nat Commun. 2025. https:\/\/doi.org\/10.1038\/s41467-025-66670-3.","journal-title":"Nat Commun"},{"key":"1299_CR62","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/216578a0","volume":"216","author":"AA Rubin","year":"1967","unstructured":"Rubin AA, Yen HC, Pfeffer M. Psychopharmacological profile of molindone. Nature. 1967;216:578\u20139. https:\/\/doi.org\/10.1038\/216578a0.","journal-title":"Nature"},{"key":"1299_CR63","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/j.1552-4604.1968.tb00270.x","volume":"8","author":"J Shelton","year":"1968","unstructured":"Shelton J, Prusmack JJ, Hollister LE. Molindone, a new type of antipsychotic drug. J Clin Pharmacol J New Drugs. 1968;8:190\u20135. https:\/\/doi.org\/10.1002\/j.1552-4604.1968.tb00270.x.","journal-title":"J Clin Pharmacol J New Drugs"},{"key":"1299_CR64","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2147\/JEP.S180777","volume":"10","author":"C Yu","year":"2018","unstructured":"Yu C, Gopalakrishnan G. In vitro pharmacological characterization of SPN-810M (molindone). J Exp Pharmacol. 2018;10:65\u201373. https:\/\/doi.org\/10.2147\/JEP.S180777.","journal-title":"J Exp Pharmacol"},{"key":"1299_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2025.106132","volume":"172","author":"C Agnorelli","year":"2025","unstructured":"Agnorelli C, Spriggs M, Godfrey K, Sawicka G, Bohl B, Douglass H, et al. Neuroplasticity and psychedelics: a comprehensive examination of classic and non-classic compounds in pre and clinical models. Neurosci Biobehav Rev. 2025;172:106132. https:\/\/doi.org\/10.1016\/j.neubiorev.2025.106132.","journal-title":"Neurosci Biobehav Rev"},{"key":"1299_CR66","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamapsychiatry.2025.0044","volume":"82","author":"L Mueller","year":"2025","unstructured":"Mueller L, Santos De Jesus J, Schmid Y, M\u00fcller F, Becker A, Klaiber A, et al. Safety and efficacy of repeated low-dose LSD for ADHD treatment in adults: a randomised clinical trial. JAMA Psychiat. 2025;82:555. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0044.","journal-title":"JAMA Psychiat"},{"key":"1299_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12868-025-00958-4","volume":"26","author":"E Kardash","year":"2025","unstructured":"Kardash E, Petrova N, Ganina K, Tarasov S, Epstein O. Pro-cognitive efficacy of Prospekta in a rat model of age-associated cognitive impairment. BMC Neurosci. 2025;26:35. https:\/\/doi.org\/10.1186\/s12868-025-00958-4.","journal-title":"BMC Neurosci"},{"key":"1299_CR68","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1002\/jemt.10303","volume":"60","author":"M Rothermundt","year":"2003","unstructured":"Rothermundt M, Peters M, Prehn JHM, Arolt V. S100B in brain damage and neurodegeneration. Microsc Res Tech. 2003;60:614\u201332. https:\/\/doi.org\/10.1002\/jemt.10303.","journal-title":"Microsc Res Tech"},{"key":"1299_CR69","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","volume":"20","author":"CH Wong","year":"2019","unstructured":"Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20:273\u201386. https:\/\/doi.org\/10.1093\/biostatistics\/kxx069.","journal-title":"Biostatistics"},{"key":"1299_CR70","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","volume":"323","author":"OJ Wouters","year":"2020","unstructured":"Wouters OJ, McKee M, Luyten J. Estimated research and development investment needed to bring a new medicine to market, 2009-2018. JAMA. 2020;323:844. https:\/\/doi.org\/10.1001\/jama.2020.1166.","journal-title":"JAMA"},{"key":"1299_CR71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s40263-021-00825-w","volume":"35","author":"RL Findling","year":"2021","unstructured":"Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, et al. Viloxazine in the management of CNS disorders: a historical overview and current status. CNS Drugs. 2021;35:643\u201353. https:\/\/doi.org\/10.1007\/s40263-021-00825-w.","journal-title":"CNS Drugs"},{"key":"1299_CR72","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/S0140-673(15)00238-X","volume":"387","author":"A Thapar","year":"2016","unstructured":"Thapar A, Cooper M. Attention deficit hyperactivity disorder. Lancet. 2016;387:1240\u201350. https:\/\/doi.org\/10.1016\/S0140-673(15)00238-X.","journal-title":"Lancet"},{"key":"1299_CR73","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.1007\/s10803-020-04685-z","volume":"51","author":"A Thapar","year":"2021","unstructured":"Thapar A, Rutter M. Genetic advances in autism. J Autism Dev Disord. 2021;51:4321\u201332. https:\/\/doi.org\/10.1007\/s10803-020-04685-z.","journal-title":"J Autism Dev Disord"},{"key":"1299_CR74","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00495-0","volume":"10","author":"SV Faraone","year":"2024","unstructured":"Faraone SV, Bellgrove MA, Brikell I, Cortese S, Hartman CA, Hollis C, et al. Attention-deficit\/hyperactivity disorder. Nat Rev Dis Primers. 2024;10:11. https:\/\/doi.org\/10.1038\/s41572-024-00495-0.","journal-title":"Nat Rev Dis Primers"},{"key":"1299_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108530","volume":"250","author":"MA Malik","year":"2023","unstructured":"Malik MA, Faraone SV, Michoel T, Haavik J. Use of big data and machine learning algorithms to extract possible treatment targets in neurodevelopmental disorders. Pharmacol Ther. 2023;250:108530. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108530.","journal-title":"Pharmacol Ther"},{"key":"1299_CR76","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1166","volume":"9","author":"C Finan","year":"2017","unstructured":"Finan C, Gaulton A, Kruger FA, Lumbers RT, Shah T, Engmann J, et al. The druggable genome and support for target identification and validation in drug development. Sci Transl Med. 2017;9:eaag1166. https:\/\/doi.org\/10.1126\/scitranslmed.aag1166.","journal-title":"Sci Transl Med"},{"key":"1299_CR77","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S2215-0366(23)00345-0","volume":"11","author":"S Cortese","year":"2024","unstructured":"Cortese S, Purper-Ouakil D, Apter A, Arango C, Baeza I, Banaschewski T, et al. Psychopharmacology in children and adolescents: unmet needs and opportunities. Lancet Psychiatry. 2024;11:143\u201354. https:\/\/doi.org\/10.1016\/S2215-0366(23)00345-0.","journal-title":"Lancet Psychiatry"},{"key":"1299_CR78","unstructured":"Thomas DW, Burns J, Audette J, Carroll A, Dow\u2010Hygelund C, Hay M. Clinical development success rates 2006\u20132015. BIO Industry Analysis; 2016."},{"key":"1299_CR79","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.molmed.2020.09.013","volume":"27","author":"S Pasteuning-Vuhman","year":"2021","unstructured":"Pasteuning-Vuhman S, De Jongh R, Timmers A, Pasterkamp RJ. Towards advanced iPSC-based drug development for neurodegenerative disease. Trends Mol Med. 2021;27:263\u201379. https:\/\/doi.org\/10.1016\/j.molmed.2020.09.013.","journal-title":"Trends Mol Med"},{"key":"1299_CR80","doi-asserted-by":"publisher","DOI":"10.3390\/cells11010069","volume":"11","author":"JFV Hunt","year":"2021","unstructured":"Hunt JFV, Li M, Risgaard R, Ananiev GE, Wildman S, Zhang F, et al. High throughput small molecule screen for reactivation of FMR1 in Fragile X syndrome human neural cells. Cells. 2021;11:69. https:\/\/doi.org\/10.3390\/cells11010069.","journal-title":"Cells"},{"key":"1299_CR81","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jamapsychiatry.2025.0303","volume":"82","author":"NTM Huneke","year":"2025","unstructured":"Huneke NTM, Cortese S, Solmi M. Understanding placebo mechanisms to reduce attrition in psychiatric trials. JAMA Psychiat. 2025;82:553. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0303.","journal-title":"JAMA Psychiat"},{"key":"1299_CR82","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2025.0085","author":"NTM Huneke","year":"2025","unstructured":"Huneke NTM, Fusetto Veronesi G, Garner M, Baldwin DS, Cortese S. Expectancy effects, failure of blinding integrity, and placebo response in trials of treatments for psychiatric disorders: a narrative review. JAMA Psychiat. 2025. https:\/\/doi.org\/10.1001\/jamapsychiatry.2025.0085.","journal-title":"JAMA Psychiat"},{"key":"1299_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaac.2024.07.926","author":"G Fusetto Veronesi","year":"2024","unstructured":"Fusetto Veronesi G, Huneke NTM, Shah M, Cortese S. Systematic review: assessment of blinding integrity in 161 randomised controlled trials of attention-deficit\/hyperactivity disorder medications. J Am Acad Child Adolesc Psychiatry. 2024. https:\/\/doi.org\/10.1016\/j.jaac.2024.07.926.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"1299_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-024-02638-x","author":"NTM Huneke","year":"2024","unstructured":"Huneke NTM, Amin J, Baldwin DS, Bellato A, Brandt V, Chamberlain SR, et al. Placebo effects in randomised trials of pharmacological and neurostimulation interventions for mental disorders: an umbrella review. Mol Psychiatry. 2024. https:\/\/doi.org\/10.1038\/s41380-024-02638-x.","journal-title":"Mol Psychiatry"},{"key":"1299_CR85","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1002\/wps.21338","volume":"24","author":"CU Correll","year":"2025","unstructured":"Correll CU, Cortese S, Solmi M, Boldrini T, Demyttenaere K, Domschke K, et al. Beyond symptom improvement: transdiagnostic and disorder\u2010specific ways to assess functional and quality of life outcomes across mental disorders in adults. World Psychiatry. 2025;24:296\u2013318. https:\/\/doi.org\/10.1002\/wps.21338.","journal-title":"World Psychiatry"},{"key":"1299_CR86","unstructured":"European Medicines Agency. Paediatric medicines: Overview | European Medicines Agency (EMA). 2015 [cited 2026 Jan 8]. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/paediatric-medicines-overview. Accessed 8 Jan 2026."},{"key":"1299_CR87","doi-asserted-by":"publisher","DOI":"10.3389\/fnbeh.2022.900981","volume":"16","author":"J Buitelaar","year":"2022","unstructured":"Buitelaar J, B\u00f6lte S, Brandeis D, Caye A, Christmann N, Cortese S, et al. Toward precision medicine in ADHD. Front Behav Neurosci. 2022;16:900981. https:\/\/doi.org\/10.3389\/fnbeh.2022.900981.","journal-title":"Front Behav Neurosci"},{"key":"1299_CR88","doi-asserted-by":"publisher","first-page":"3865","DOI":"10.1038\/s41380-024-02606-5","volume":"29","author":"G Salazar de Pablo","year":"2024","unstructured":"Salazar de Pablo G, Iniesta R, Bellato A, Caye A, Dobrosavljevic M, Parlatini V, et al. Individualized prediction models in ADHD: a systematic review and meta-regression. Mol Psychiatry. 2024;29:3865\u201373. https:\/\/doi.org\/10.1038\/s41380-024-02606-5.","journal-title":"Mol Psychiatry"},{"key":"1299_CR89","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jamapsychiatry.2018.2530","volume":"75","author":"P Fusar-Poli","year":"2018","unstructured":"Fusar-Poli P, Hijazi Z, Stahl D, Steyerberg EW. The science of prognosis in psychiatry: a review. JAMA Psychiat. 2018;75:1289. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.2530.","journal-title":"JAMA Psychiat"},{"key":"1299_CR90","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-021-03040-5","volume":"21","author":"J-C Chang","year":"2021","unstructured":"Chang J-C, Lin H-Y, Lv J, Tseng W-YI, Gau SS-F. Regional brain volume predicts response to methylphenidate treatment in individuals with ADHD. BMC Psychiatry. 2021;21:26. https:\/\/doi.org\/10.1186\/s12888-021-03040-5.","journal-title":"BMC Psychiatry"},{"key":"1299_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-022-01832-1","volume":"12","author":"L-J Wang","year":"2022","unstructured":"Wang L-J, Kuo H-C, Lee S-Y, Huang L-H, Lin Y, Lin P-H, et al. MicroRNAs serve as prediction and treatment-response biomarkers of attention-deficit\/hyperactivity disorder and promote the differentiation of neuronal cells by repressing the apoptosis pathway. Transl Psychiatry. 2022;12:67. https:\/\/doi.org\/10.1038\/s41398-022-01832-1.","journal-title":"Transl Psychiatry"},{"key":"1299_CR92","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2020.113664","volume":"296","author":"SV Faraone","year":"2021","unstructured":"Faraone SV, Gomeni R, Hull JT, Busse GD, Melyan Z, O\u2019Neal W, et al. Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials. Psychiatry Res. 2021;296:113664. https:\/\/doi.org\/10.1016\/j.psychres.2020.113664.","journal-title":"Psychiatry Res"},{"key":"1299_CR93","doi-asserted-by":"publisher","DOI":"10.1093\/ijnp\/pyv052","volume":"18","author":"J-W Kim","year":"2015","unstructured":"Kim J-W, Sharma V, Ryan ND. Predicting methylphenidate response in ADHD using machine learning approaches. Int J Neuropsychopharmacol. 2015;18:pyv052. https:\/\/doi.org\/10.1093\/ijnp\/pyv052.","journal-title":"Int J Neuropsychopharmacol"},{"key":"1299_CR94","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1007\/s10488-020-01045-y","volume":"47","author":"AS Morrow","year":"2020","unstructured":"Morrow AS, Campos Vega AD, Zhao X, Liriano MM. Leveraging machine learning to identify predictors of receiving psychosocial treatment for attention deficit\/hyperactivity disorder. Adm Policy Ment Health. 2020;47:680\u201392. https:\/\/doi.org\/10.1007\/s10488-020-01045-y.","journal-title":"Adm Policy Ment Health"},{"key":"1299_CR95","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.jval.2015.06.005","volume":"18","author":"J Setyawan","year":"2015","unstructured":"Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, et al. Developing a risk score to guide individualized treatment selection in attention deficit\/hyperactivity disorder. Value Health. 2015;18:824\u201331. https:\/\/doi.org\/10.1016\/j.jval.2015.06.005.","journal-title":"Value Health"},{"key":"1299_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00199","volume":"8","author":"HK Wong","year":"2017","unstructured":"Wong HK, Tiffin PA, Chappell MJ, Nichols TE, Welsh PR, Doyle OM, et al. Personalized medication response prediction for attention-deficit hyperactivity disorder: learning in the model space vs. learning in the data space. Front Physiol. 2017;8:199. https:\/\/doi.org\/10.3389\/fphys.2017.00199.","journal-title":"Front Physiol"},{"key":"1299_CR97","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.jclinepi.2004.06.017","volume":"58","author":"Y Vergouwe","year":"2005","unstructured":"Vergouwe Y, Steyerberg EW, Eijkemans MJC, Habbema JDF. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol. 2005;58:475\u201383. https:\/\/doi.org\/10.1016\/j.jclinepi.2004.06.017.","journal-title":"J Clin Epidemiol"},{"key":"1299_CR98","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1176\/appi.ajp.2021.20091342","volume":"178","author":"LJ Norman","year":"2021","unstructured":"Norman LJ, Sudre G, Bouyssi-Kobar M, Sharp W, Shaw P. A longitudinal study of resting-state connectivity and response to psychostimulant treatment in ADHD. Am J Psychiatry. 2021;178:744\u201351. https:\/\/doi.org\/10.1176\/appi.ajp.2021.20091342.","journal-title":"Am J Psychiatry"},{"key":"1299_CR99","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1176\/appi.ajp.2021.21050549","volume":"178","author":"S Cortese","year":"2021","unstructured":"Cortese S. Setting the foundations of developmental precision psychiatry for ADHD. Am J Psychiatry. 2021;178:677\u20139. https:\/\/doi.org\/10.1176\/appi.ajp.2021.21050549.","journal-title":"Am J Psychiatry"},{"key":"1299_CR100","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.chc.2007.11.009","volume":"17","author":"MA Stein","year":"2008","unstructured":"Stein MA, McGough JJ. The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am. 2008;17:475\u201390. https:\/\/doi.org\/10.1016\/j.chc.2007.11.009.","journal-title":"Child Adolesc Psychiatr Clin N Am"},{"key":"1299_CR101","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s40263-020-00702-y","volume":"34","author":"NA Elsayed","year":"2020","unstructured":"Elsayed NA, Yamamoto KM, Froehlich TE. Genetic influence on efficacy of pharmacotherapy for paediatric attention-deficit\/hyperactivity disorder: overview and current status of research. CNS Drugs. 2020;34:389\u2013414. https:\/\/doi.org\/10.1007\/s40263-020-00702-y.","journal-title":"CNS Drugs"},{"key":"1299_CR102","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.2174\/138161210791959872","volume":"16","author":"G Polanczyk","year":"2010","unstructured":"Polanczyk G, Bigarella MP, Hutz MH, Rohde LA. Pharmacogenetic approach for a better drug treatment in children. Curr Pharm Des. 2010;16:2462\u201373. https:\/\/doi.org\/10.2174\/138161210791959872.","journal-title":"Curr Pharm Des"},{"key":"1299_CR103","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1002\/cpt.1409","volume":"106","author":"JT Brown","year":"2019","unstructured":"Brown JT, Bishop JR, Sangkuhl K, Nurmi EL, Mueller DJ, Dinh JC, et al. Clinical pharmacogenetics implementation consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106:94\u2013102. https:\/\/doi.org\/10.1002\/cpt.1409.","journal-title":"Clin Pharmacol Ther"},{"key":"1299_CR104","doi-asserted-by":"publisher","DOI":"10.1038\/mp.2017.234","author":"NM Myer","year":"2017","unstructured":"Myer NM. Pharmacogenetics predictors of methylphenidate efficacy in childhood ADHD. Mol Psychiatry. 2017. https:\/\/doi.org\/10.1038\/mp.2017.234.","journal-title":"Mol Psychiatry"},{"key":"1299_CR105","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1176\/appi.ajp.2020.20121686","volume":"178","author":"I Brikell","year":"2021","unstructured":"Brikell I, Wimberley T, Albi\u00f1ana C, Pedersen EM, Vilhj\u00e1lmsson BJ, Agerbo E, et al. Genetic, clinical, and sociodemographic factors associated with stimulant treatment outcomes in ADHD. Am J Psychiatry. 2021;178:854\u201364. https:\/\/doi.org\/10.1176\/appi.ajp.2020.20121686.","journal-title":"Am J Psychiatry"},{"key":"1299_CR106","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-024-02998-6","volume":"14","author":"NT Sharew","year":"2024","unstructured":"Sharew NT, Clark SR, Schubert KO, Amare AT. Pharmacogenomic scores in psychiatry: systematic review of current evidence. Transl Psychiatry. 2024;14:322. https:\/\/doi.org\/10.1038\/s41398-024-02998-6.","journal-title":"Transl Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01299-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01299-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T09:47:15Z","timestamp":1782380835000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01299-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":106,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1299"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01299-4","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"9 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SC has declared reimbursement for travel and accommodation expenses from the Association for Child and Adolescent Central Health (ACAMH) in relation to lectures delivered for ACAMH, the Canadian AADHD Alliance Resource, the British Association of Psychopharmacology, Healthcare Convention and CCM Group team for educational activity on ADHD and has received honoraria from Medice. SC is an Editorial Board member of CNS Drugs. SC was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. The other authors declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the study conception, design, literature search, data collection, and analysis. The first draft of the manuscript was written by GFV, and all authors commented on the various versions of the manuscript. All authors read and approved the final manuscript and agree to be accountable for all aspects of the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}